XOMA Corporation (XOMA) Shares are Down -2.49%

XOMA Corporation (XOMA) : During the past 4 weeks, traders have been relatively bearish on XOMA Corporation (XOMA), hence the stock is down -14.08% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.85% relative to the S&P 500. The 4-week change in the price of the stock is -14.26% and the stock has fallen -2.49% in the past 1 week.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 6.3% and the fifty day Moving Average is 0.3%. XOMA Corporation has dropped 17.81% during the last three month period . Year-to-Date the stock performance stands at -56.74%.

XOMA Corporation (XOMA) : 3 Wall Street analysts covering XOMA Corporation (XOMA) believe that the average level the stock could reach for the short term is $1.62. The maximum price target given is $3 and the minimum target for short term is around $1, hence the standard deviation is calculated at $1.2.


XOMA Corporation (NASDAQ:XOMA): On Fridays trading session , Opening price of the stock was $0.57 with an intraday high of $0.59. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.57. However, the stock managed to close at $0.5753, a loss of 0.47% for the day. On the previous day, the stock had closed at $0.578. The total traded volume of the day was 408,513 shares.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.